Companies in #Inflammatory Bowel Disease

Oxford University spin-out applying high-resolution native mass spectrometry through its OdyssION platform to drug membrane proteins and intracellular complexes that have historically been undruggable, with small-molecule programs in orphan endocrine and immunological disease.

Palatin Technologies is a biopharmaceutical company developing first-in-class medicines that modulate the melanocortin receptor (MCR) system, focused on rare and complex obesity, ocular, and inflammatory conditions. Its MC4R-based obesity franchise includes oral small-molecule PL7737 and once-weekly long-acting peptide MC4R agonists targeting hypothalamic obesity and Prader-Willi syndrome, plus a Phase 2 combination of bremelanotide with tirzepatide. Additional programs include PL9643 for dry eye disease and oral PL8177 for inflammatory bowel disease. The company up-listed to Nasdaq in May 2026 after a 2025 restructuring, and its Boehringer Ingelheim collaboration provides non-dilutive funding and milestones.

Pasithea Therapeutics is a clinical-stage biotechnology company developing small-molecule and antibody therapies for RASopathies, MAPK pathway-driven tumours and central nervous system disorders. Its lead candidate, PAS-004, is a next-generation macrocyclic MEK inhibitor designed for chronic dosing with a long half-life and partial pathway inhibition intended to widen the therapeutic window relative to earlier MEK inhibitors; it is in a Phase 1b dose-escalation study in adults with neurofibromatosis type 1, with cutaneous neurofibromas as the primary development focus and additional potential in BRAF-driven tumours and ETS2-driven inflammatory disease. The company is also developing PAS-003 for amyotrophic lateral sclerosis and PAS-001 for schizophrenia. Pasithea was founded in 2020 by Dr. Lawrence Steinman and listed on Nasdaq in September 2021; it is headquartered in Miami Beach, Florida and operates with a small team of five employees.

Triveni Bio is a private clinical-stage biotechnology company developing novel antibody therapeutics for immune and inflammatory diseases using a genetics-informed precision medicine approach. The company raised $65M in June 2026 ahead of upcoming readouts on its lead eczema drug programs, advancing first-in-class functional antibodies for I&I disorders with defined genetic patient stratification strategies.